HomeCompareMKUL vs JNJ

MKUL vs JNJ: Dividend Comparison 2026

MKUL yields 3696.86% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MKUL wins by $3359133543993.44M in total portfolio value
10 years
MKUL
MKUL
● Live price
3696.86%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3359133543993.47M
Annual income
$3,189,419,904,659,486,700.00
Full MKUL calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — MKUL vs JNJ

📍 MKUL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMKULJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MKUL + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MKUL pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MKUL
Annual income on $10K today (after 15% tax)
$314,232.90/yr
After 10yr DRIP, annual income (after tax)
$2,711,006,918,960,563,700.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, MKUL beats the other by $2,711,006,918,960,559,600.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MKUL + JNJ for your $10,000?

MKUL: 50%JNJ: 50%
100% JNJ50/50100% MKUL
Portfolio after 10yr
$1679566771996.75M
Annual income
$1,594,709,952,329,745,700.00/yr
Blended yield
94.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MKUL
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-0.8
Piotroski
0/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MKUL buys
0
JNJ buys
0
No recent congressional trades found for MKUL or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMKULJNJ
Forward yield3696.86%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$3359133543993.47M$30.5K
Annual income after 10y$3,189,419,904,659,486,700.00$4,749.88
Total dividends collected$3347517978690.71M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: MKUL vs JNJ ($10,000, DRIP)

YearMKUL PortfolioMKUL Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$380,386$369,685.77$10,594$274.49+$369.8KMKUL
2$13,549,368$13,142,355.52$11,294$360.69+$13.54MMKUL
3$452,004,035$437,506,211.16$12,133$476.91+$451.99MMKUL
4$14,123,937,638$13,640,293,320.21$13,156$635.42+$14123.92MMKUL
5$413,452,147,440$398,339,534,167.11$14,432$854.61+$413452.13MMKUL
6$11,340,200,341,285$10,897,806,543,524.30$16,056$1,162.76+$11340200.33MMKUL
7$291,485,375,324,008$279,351,360,958,833.72$18,175$1,604.53+$291485375.31MMKUL
8$7,022,515,682,323,467$6,710,626,330,726,778.00$21,009$2,252.68+$7022515682.30MMKUL
9$158,610,877,882,230,980$151,096,786,102,144,860.00$24,911$3,229.73+$158610877882.21MMKUL
10$3,359,133,543,993,474,000$3,189,419,904,659,486,700.00$30,458$4,749.88+$3359133543993.44MMKUL

MKUL vs JNJ: Complete Analysis 2026

MKULStock

Molekule Group, Inc., an interior space air purification technology company, provides air purification solutions for hospitals and other healthcare facilities. The company offers interior air sterilization and disinfection products for the eradication of harmful airborne pathogens, including COVID-19. Its air hygiene product, Purgo (pure-go), a medical device that provides continuous air filtration, sanitization, and supplemental ventilation solutions with technology applied in any indoor space, including in hospitals, offices, and elevators. The company's Purgo products feature SteriDuct, a proprietary germicidal technology that work to equipment and devices to reduce the exposure of occupants of interior spaces to airborne particles and pathogens; Air Mini+, a direct-to-consumer air purifier, which features include a particle sensor, five fan speeds, and automatic fan speed adjustment through the product's auto protect mode; Air Pro, a direct-to-consumer and business-to-business product for rooms of up to 1,000 square feet; and Air Pro Rx, a medical-grade purifier designed for traffic areas in healthcare facilities for rooms more than 600 square feet. It also offers PECO-HEPA Tri-Power filter; Molekule App, a mobile application that provides a 28 day look back of IAQ trends sensed by the Air Pro air purifier, breaking down pollutants detected, including VOCs, and pollutants that range from PM 1 to PM 10 in size; and Molekule Air Platform, a dashboard that allows data from multiple air purifiers and controls to be accessed in one interface. The company was formerly known as AeroClean Technologies, Inc. and changed its name to Molekule Group, Inc. in January 2023. Molekule Group, Inc. was founded in 2011 and is headquartered in Palm Beach Gardens, Florida.

Full MKUL Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MKUL vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MKUL vs SCHDMKUL vs JEPIMKUL vs OMKUL vs KOMKUL vs MAINMKUL vs ABBVMKUL vs MRKMKUL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.